Mucormycosis in Children

Review and Recommendations for Management

Joshua R. Francis, Paola Villanueva, Penelope Bryant, Christopher C. Blyth

    Research output: Contribution to journalReview articleResearchpeer-review

    Abstract

    Mucormycosis represents the third most common invasive fungal infection in children, and recent studies have suggested a rising incidence. Its case fatality rate is high, especially for neonates. Clinical presentation is influenced by underlying risk factors; associations with immunosuppression, neutropenia, diabetes, and prematurity have been described. It has been implicated in several hospital outbreaks. Diagnosis requires a high index of suspicion and evaluation with histopathology, culture, and, increasingly, molecular identification. Surgical debridement and antifungal therapies are the cornerstone for combatting invasive mucormycosis. However, the severity and relative rarity of this disease make comparative clinical trials for evaluating antifungal therapies in children difficult to conduct. Hence, therapeutic decisions are derived mainly from retrospective case series, in vitro data, and animal models. In this review, we summarize the literature on the epidemiology and diagnosis of this invasive fungal infection and provide suggestions on the management of mucormycosis in children.

    Original languageEnglish
    Pages (from-to)159-164
    Number of pages6
    JournalJournal of the Pediatric Infectious Diseases Society
    Volume7
    Issue number2
    DOIs
    Publication statusPublished - 15 May 2018

    Fingerprint

    Mucormycosis
    Debridement
    Neutropenia
    Immunosuppression
    Disease Outbreaks
    Epidemiology
    Therapeutics
    Animal Models
    Clinical Trials
    Newborn Infant
    Mortality
    Incidence
    Invasive Fungal Infections

    Cite this

    Francis, Joshua R. ; Villanueva, Paola ; Bryant, Penelope ; Blyth, Christopher C. / Mucormycosis in Children : Review and Recommendations for Management. In: Journal of the Pediatric Infectious Diseases Society. 2018 ; Vol. 7, No. 2. pp. 159-164.
    @article{1337b72fc26f4f8db56a5337cece1bd7,
    title = "Mucormycosis in Children: Review and Recommendations for Management",
    abstract = "Mucormycosis represents the third most common invasive fungal infection in children, and recent studies have suggested a rising incidence. Its case fatality rate is high, especially for neonates. Clinical presentation is influenced by underlying risk factors; associations with immunosuppression, neutropenia, diabetes, and prematurity have been described. It has been implicated in several hospital outbreaks. Diagnosis requires a high index of suspicion and evaluation with histopathology, culture, and, increasingly, molecular identification. Surgical debridement and antifungal therapies are the cornerstone for combatting invasive mucormycosis. However, the severity and relative rarity of this disease make comparative clinical trials for evaluating antifungal therapies in children difficult to conduct. Hence, therapeutic decisions are derived mainly from retrospective case series, in vitro data, and animal models. In this review, we summarize the literature on the epidemiology and diagnosis of this invasive fungal infection and provide suggestions on the management of mucormycosis in children.",
    author = "Francis, {Joshua R.} and Paola Villanueva and Penelope Bryant and Blyth, {Christopher C.}",
    year = "2018",
    month = "5",
    day = "15",
    doi = "10.1093/jpids/pix107",
    language = "English",
    volume = "7",
    pages = "159--164",
    journal = "Journal of the Pediatric Infectious Diseases Society",
    issn = "2048-7193",
    publisher = "Oxford University Press",
    number = "2",

    }

    Mucormycosis in Children : Review and Recommendations for Management. / Francis, Joshua R.; Villanueva, Paola; Bryant, Penelope; Blyth, Christopher C.

    In: Journal of the Pediatric Infectious Diseases Society, Vol. 7, No. 2, 15.05.2018, p. 159-164.

    Research output: Contribution to journalReview articleResearchpeer-review

    TY - JOUR

    T1 - Mucormycosis in Children

    T2 - Review and Recommendations for Management

    AU - Francis, Joshua R.

    AU - Villanueva, Paola

    AU - Bryant, Penelope

    AU - Blyth, Christopher C.

    PY - 2018/5/15

    Y1 - 2018/5/15

    N2 - Mucormycosis represents the third most common invasive fungal infection in children, and recent studies have suggested a rising incidence. Its case fatality rate is high, especially for neonates. Clinical presentation is influenced by underlying risk factors; associations with immunosuppression, neutropenia, diabetes, and prematurity have been described. It has been implicated in several hospital outbreaks. Diagnosis requires a high index of suspicion and evaluation with histopathology, culture, and, increasingly, molecular identification. Surgical debridement and antifungal therapies are the cornerstone for combatting invasive mucormycosis. However, the severity and relative rarity of this disease make comparative clinical trials for evaluating antifungal therapies in children difficult to conduct. Hence, therapeutic decisions are derived mainly from retrospective case series, in vitro data, and animal models. In this review, we summarize the literature on the epidemiology and diagnosis of this invasive fungal infection and provide suggestions on the management of mucormycosis in children.

    AB - Mucormycosis represents the third most common invasive fungal infection in children, and recent studies have suggested a rising incidence. Its case fatality rate is high, especially for neonates. Clinical presentation is influenced by underlying risk factors; associations with immunosuppression, neutropenia, diabetes, and prematurity have been described. It has been implicated in several hospital outbreaks. Diagnosis requires a high index of suspicion and evaluation with histopathology, culture, and, increasingly, molecular identification. Surgical debridement and antifungal therapies are the cornerstone for combatting invasive mucormycosis. However, the severity and relative rarity of this disease make comparative clinical trials for evaluating antifungal therapies in children difficult to conduct. Hence, therapeutic decisions are derived mainly from retrospective case series, in vitro data, and animal models. In this review, we summarize the literature on the epidemiology and diagnosis of this invasive fungal infection and provide suggestions on the management of mucormycosis in children.

    UR - http://www.scopus.com/inward/record.url?scp=85055613564&partnerID=8YFLogxK

    U2 - 10.1093/jpids/pix107

    DO - 10.1093/jpids/pix107

    M3 - Review article

    VL - 7

    SP - 159

    EP - 164

    JO - Journal of the Pediatric Infectious Diseases Society

    JF - Journal of the Pediatric Infectious Diseases Society

    SN - 2048-7193

    IS - 2

    ER -